- Biodexa Pharmaceuticals PLC reported unaudited interim results for the **six months ended June 30, 2025**, with a net cash inflow of **£2.37 million** for the period, bringing the cash balance to **£4.04 million** as of that date.  **[1643918_0001214659-25-013673_ex99_1.htm:0]** **[1643918_0001214659-25-013673_ex99_1.htm:4]** **[1643918_0001214659-25-013673_ex99_1.htm:5]** 
- The company secured a **$35 million** Equity Line of Credit (ELOC) in January 2025, from which it had raised **$8.56 million** in gross proceeds by **June 30, 2025**.  **[1643918_0001214659-25-013673_ex99_1.htm:0]** **[1643918_0001214659-25-013673_ex99_1.htm:4]** 
- Operationally, Biodexa advanced its R&D pipeline, notably with the recruitment of the first patients in the pivotal Serenta trial (eRapa in FAP) and obtaining Orphan Drug Designation for eRapa in FAP from the European Commission.  **[1643918_0001214659-25-013673_ex99_1.htm:0]** **[1643918_0001214659-25-013673_ex99_1.htm:2]** 
- The company reported an accumulated deficit of **£154.13 million** as of **June 30, 2025**, and stated that further financing will be required before the **second quarter of 2026**, highlighting a material uncertainty regarding its ability to continue as a going concern.  **[1643918_0001214659-25-013673_ex99_1.htm:5]** **[1643918_0001214659-25-013673_ex99_1.htm:8]**

Biodexa Pharmaceuticals (BDRX)